FDA OKs Biohaven’s Sublingual BHV-0223 for Clinical Investigation
The U.S. Food and Drug Administration (FDA) has given the green light to Biohaven Pharmaceuticals to advance sublingual BHV-0223, which regulates glutamate communication between neurons, into clinical trials for amyotrophic lateral sclerosis (ALS) patients. The FDA’s permission to go ahead with the study followed Biohaven’s submission of an investigational new drug…